Acute Mania
Conditions
Keywords
Acute Mania, Mania, Adults, Seroquel, Acute Mania in Adult Patients
Brief summary
The purpose of this study is to determine if lithium 600-1800 mg/day is effective when added to quetiapine fumarate extended release (quetiapine XR or SEROQUEL® XR) 400-800 mg/day in treating acute mania and if so, how it compares with placebo (a non-active capsule, like a sugar pill, that looks like lithium).
Interventions
Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
Oral treatment twice daily.
Sponsors
Study design
Eligibility
Inclusion criteria
* Provision of informed consent before any study procedures are performed. * The patient must have a documented clinical diagnosis for bipolar I disorder, including recent episode manic or mixed, and being male of females age 18-65 years, inclusive. * Patients may be outpatients or inpatients at enrollment visit, but all patients must be inpatients when randomized and remain inpatients until discharged at the discretion of the investigator.
Exclusion criteria
* The patient can not have had up to 8 mood episodes during the past 12 months and not been continuously hospitalized for acute bipolar for up to 3 weeks immediately before participating in the study. * The patient can not have a past diagnosis of stroke or medically documented transient ischemic attacks (TIA) or a history of seizure disorder, except for febrile convulsions. * The patient must not have received electroconvulsive treatment (ECT) within 90 days before participating in the study and in the doctors judgement pose a current suicidal or homicidal risk.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43) | Change in YMRS total score from baseline to Day 43. | The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Remission | Days 8 to 43 | The number of patients with clinically significant remission (defined as YMRS total score ≤12) from Days 8 to 43) was calculated. The Young Mania Rating Scale total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania). |
| Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness) | Change from baseline to Day 43. | The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity. |
| Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase) | Change from baseline to Day 43 | The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement. |
| Improvement of Overall Bipolar Illness | Day 43. | The number of patients with a CGI-BP-C of Much or Very much improved in overall bipolar illness assessment at Day 43 was calculated. The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement. |
| Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change from baseline to Day 43. | The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms. |
| Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score | Change from baseline to Day 43 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210.A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in PANSS Activation Subscale Score | Change from baseline to Day 43 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in PANSS Positive Subscale Score | Change from baseline to Day 43 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 1 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 1 (Elevated mood) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| The Number of Patients With Clinically Significant Response. | 43 days (from baseline to Day 43) | The number of patients with clinically significant response (defined as ≥50% reduction from baseline to Day 43 in the YMRS total score) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 3 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 3 (sexual interest) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 4 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 5 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 5 (Irritability) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 6 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 6 (speech-rate and amount) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 7 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 7 (language-thought disorder) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 8 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 8 (content) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 9 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. . This analysis is for Item 9 (disruptive-aggressive behavior) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 10 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 10 (appearance) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 11 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 11 (insight) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
| Change From Baseline to Day 43 in Each YMRS Item Score No. 2 | Change from baseline to Day 43 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 2 (increased motor activity-energy) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. |
Countries
Belgium, Bulgaria, Germany, India, Israel, Poland, Russia, South Africa, Ukraine
Participant flow
Recruitment details
This multicenter study was conducted between 24 June 2009 and 22 November 2010.
Pre-assignment details
The study had an up to 28-day enrollment period (including a washout period lasting 7 to 28 days) and a 6-week double-blind treatment period. Patients were randomized to receive lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day or placebo+quetiapine XR 400 to 800 mg/day.
Participants by arm
| Arm | Count |
|---|---|
| Lithium+Quetiapine XR Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | 173 |
| Placebo+Quetiapine XR Placebo+quetiapine XR 400 to 800 mg/day | 183 |
| Total | 356 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 6 | 13 |
| Overall Study | Condition under investigation worsened | 1 | 2 |
| Overall Study | Lack or insufficient theraputic response | 2 | 5 |
| Overall Study | Late hospital discharge | 1 | 0 |
| Overall Study | Lithium found in blood | 0 | 1 |
| Overall Study | Lost to Follow-up | 1 | 2 |
| Overall Study | Safety reasons | 0 | 1 |
| Overall Study | Severe non-compliance to protocol | 2 | 0 |
| Overall Study | Sponsor decision | 1 | 0 |
| Overall Study | Study-specific discontinuation criteria | 1 | 1 |
| Overall Study | Took prohibited concomitant medication | 0 | 1 |
| Overall Study | Withdrawal by Subject | 11 | 13 |
Baseline characteristics
| Characteristic | Lithium+Quetiapine XR | Placebo+Quetiapine XR | Total |
|---|---|---|---|
| Age Continuous | 37.9 Years STANDARD_DEVIATION 12.71 | 38.8 Years STANDARD_DEVIATION 12.09 | 38.3 Years STANDARD_DEVIATION 12.39 |
| Sex: Female, Male Female | 72 Participants | 62 Participants | 134 Participants |
| Sex: Female, Male Male | 101 Participants | 121 Participants | 222 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 106 / 173 | 83 / 183 |
| serious Total, serious adverse events | 4 / 173 | 8 / 183 |
Outcome results
Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43)
The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).
Time frame: Change in YMRS total score from baseline to Day 43.
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43) | -22.8 Scores on a scale | Standard Error 0.706 |
| Placebo+Quetiapine XR | Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43) | -20.1 Scores on a scale | Standard Error 0.711 |
Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase)
The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase) | 1.7 Scores on a scale | Standard Error 0.085 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase) | 1.9 Scores on a scale | Standard Error 0.086 |
Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness)
The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity.
Time frame: Change from baseline to Day 43.
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness) | -2.5 Scores on a scale | Standard Error 0.079 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness) | -2.2 Scores on a scale | Standard Error 0.08 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 1
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 1 (Elevated mood) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 1 | -1.8 Scores on a scale | Standard Error 0.079 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 1 | -1.6 Scores on a scale | Standard Error 0.08 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 10
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 10 (appearance) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 10 | -1.1 Scores on a scale | Standard Error 0.057 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 10 | -1.0 Scores on a scale | Standard Error 0.057 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 11
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 11 (insight) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 11 | -1.4 Scores on a scale | Standard Error 0.069 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 11 | -1.2 Scores on a scale | Standard Error 0.07 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 2
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 2 (increased motor activity-energy) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 2 | -1.9 Scores on a scale | Standard Error 0.071 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 2 | -1.7 Scores on a scale | Standard Error 0.072 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 3
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 3 (sexual interest) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 3 | -1.3 Scores on a scale | Standard Error 0.063 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 3 | -1.1 Scores on a scale | Standard Error 0.064 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 4
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 4 | -2.0 Scores on a scale | Standard Error 0.085 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 4 | -1.8 Scores on a scale | Standard Error 0.086 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 5
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 5 (Irritability) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 5 | -3.1 Scores on a scale | Standard Error 0.109 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 5 | -2.8 Scores on a scale | Standard Error 0.11 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 6
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 6 (speech-rate and amount) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 6 | -3.1 Scores on a scale | Standard Error 0.116 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 6 | -2.9 Scores on a scale | Standard Error 0.118 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 7
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 7 (language-thought disorder) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 7 | -1.5 Scores on a scale | Standard Error 0.071 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 7 | -1.4 Scores on a scale | Standard Error 0.072 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 8
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 8 (content) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 8 | -3.1 Scores on a scale | Standard Error 0.132 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 8 | -2.9 Scores on a scale | Standard Error 0.133 |
Change From Baseline to Day 43 in Each YMRS Item Score No. 9
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. . This analysis is for Item 9 (disruptive-aggressive behavior) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 9 | -2.5 Scores on a scale | Standard Error 0.088 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Each YMRS Item Score No. 9 | -2.1 Scores on a scale | Standard Error 0.089 |
Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms.
Time frame: Change from baseline to Day 43.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -4.8 Scores on a scale | Standard Error 0.366 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -4.1 Scores on a scale | Standard Error 0.368 |
Change From Baseline to Day 43 in PANSS Activation Subscale Score
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in PANSS Activation Subscale Score | -7.1 Scores on a scale | Standard Error 0.281 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in PANSS Activation Subscale Score | -5.9 Scores on a scale | Standard Error 0.283 |
Change From Baseline to Day 43 in PANSS Positive Subscale Score
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in PANSS Positive Subscale Score | -8.1 Scores on a scale | Standard Error 0.316 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in PANSS Positive Subscale Score | -7.0 Scores on a scale | Standard Error 0.316 |
Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210.A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Lithium+Quetiapine XR | Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score | -19.2 Scores on a scale | Standard Error 0.914 |
| Placebo+Quetiapine XR | Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score | -15.6 Scores on a scale | Standard Error 0.914 |
Improvement of Overall Bipolar Illness
The number of patients with a CGI-BP-C of Much or Very much improved in overall bipolar illness assessment at Day 43 was calculated. The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.
Time frame: Day 43.
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lithium+Quetiapine XR | Improvement of Overall Bipolar Illness | 134 Participants |
| Placebo+Quetiapine XR | Improvement of Overall Bipolar Illness | 125 Participants |
Remission
The number of patients with clinically significant remission (defined as YMRS total score ≤12) from Days 8 to 43) was calculated. The Young Mania Rating Scale total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).
Time frame: Days 8 to 43
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lithium+Quetiapine XR | Remission | 125 Participants |
| Placebo+Quetiapine XR | Remission | 105 Participants |
The Number of Patients With Clinically Significant Response.
The number of patients with clinically significant response (defined as ≥50% reduction from baseline to Day 43 in the YMRS total score) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.
Time frame: 43 days (from baseline to Day 43)
Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lithium+Quetiapine XR | The Number of Patients With Clinically Significant Response. | 137 Participants |
| Placebo+Quetiapine XR | The Number of Patients With Clinically Significant Response. | 120 Participants |